BIOLASE Wins Motion to Dismiss Shareholder Class Action Lawsuit

19 January 2006

BIOLASE Technology, Inc., (NASDAQ: BLTI) a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine, announced today that the United States District Court for the Central District of California has dismissed without prejudice all claims against the Company and its officers and directors in the consolidated shareholder class action lawsuits filed starting in August 2004. The suits alleged that BIOLASE failed to disclose material information, made false statements and took actions to artificially inflate and maintain the market price of the Company's common stock during the class period of October 29, 2003 to July 16, 2004. BIOLASE's motion to dismiss the second amended consolidated class action complaint was granted and the action was dismissed by the order of the Honorable David O. Carter, United States District Judge for the Central District of California. The court gave the plaintiffs 30 days to amend their complaint.

"We are very pleased that this class action has been dismissed," commented Robert E. Grant, President and CEO. "We look forward to putting this litigation behind us."

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com) is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. The Company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase® system, is the best selling dental laser system. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The Company also offers the LaserSmile™ system, which uses a laser to perform soft tissue and cosmetic procedures, including tooth whitening.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements in this release include statements relating to the positive ruling in the shareholder class action lawsuit and the timing thereof. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

For further information, please contact: Robert E. Grant, President & CEO; Richard L. Harrison, Executive Vice President and CFO; or Scott Jorgensen, Director of Finance & Investor Relations, of BIOLASE Technology, Inc., +1-949-361-1200.

For further information, please contact:

Robert E. Grant

President & CEO

Richard L. Harrison

Executive Vice President and CFO

Scott Jorgensen

Director of Finance & Investor Relations

BIOLASE Technology, Inc.

+1-949-361-1200

SOURCE: BIOLASE Technology, Inc.

Source: marketwire

All trademarks and copyrighted information contained herein are the property of their respective owners.